CL2020002719A1 - Moduladores de nlrp3 - Google Patents
Moduladores de nlrp3Info
- Publication number
- CL2020002719A1 CL2020002719A1 CL2020002719A CL2020002719A CL2020002719A1 CL 2020002719 A1 CL2020002719 A1 CL 2020002719A1 CL 2020002719 A CL2020002719 A CL 2020002719A CL 2020002719 A CL2020002719 A CL 2020002719A CL 2020002719 A1 CL2020002719 A1 CL 2020002719A1
- Authority
- CL
- Chile
- Prior art keywords
- nlrp3
- modulators
- nlrp3 modulators
- compounds
- medicaments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención proporciona compuestos de Fórmula (I): en el que todas las variables son como se definen en el presente documento. Estos compuestos son moduladores de NLRP3, que pueden ser utilizados como medicamentos para el tratamiento de trastornos proliferativos, tales como cáncer en un sujeto (por ejemplo, un ser humano).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662240P | 2018-04-25 | 2018-04-25 | |
US201862764818P | 2018-08-16 | 2018-08-16 | |
US201962825044P | 2019-03-28 | 2019-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002719A1 true CL2020002719A1 (es) | 2020-12-18 |
Family
ID=66677224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002719A CL2020002719A1 (es) | 2018-04-25 | 2020-10-21 | Moduladores de nlrp3 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210267964A1 (es) |
EP (2) | EP3784670B1 (es) |
JP (2) | JP7351850B2 (es) |
KR (1) | KR20210005106A (es) |
CN (2) | CN112074516A (es) |
AU (1) | AU2019261582A1 (es) |
BR (1) | BR112020021539A2 (es) |
CA (1) | CA3097865A1 (es) |
CL (1) | CL2020002719A1 (es) |
CO (2) | CO2021006672A2 (es) |
IL (1) | IL278173A (es) |
MX (1) | MX2020011234A (es) |
PE (1) | PE20210160A1 (es) |
SG (1) | SG11202010463TA (es) |
TW (1) | TW202014420A (es) |
WO (1) | WO2019209896A1 (es) |
ZA (1) | ZA202007307B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
IL297165A (en) * | 2020-04-16 | 2022-12-01 | Incyte Corp | Soysag tricyclic CRS inhibitors |
US20230183249A1 (en) | 2020-04-30 | 2023-06-15 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
WO2022037631A1 (zh) * | 2020-08-21 | 2022-02-24 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
EP3984535A1 (en) * | 2020-10-16 | 2022-04-20 | Albert-Ludwigs-Universität Freiburg | Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome |
CN114539095A (zh) * | 2020-11-26 | 2022-05-27 | 乐凯化学材料有限公司 | 3-(4-羟基-3-甲氧基-苯基)-2-氰基-2-丙烯酸乙酯的制备方法 |
AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US20070259907A1 (en) * | 2004-06-18 | 2007-11-08 | Prince Ryan B | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
PT2573073E (pt) | 2011-09-26 | 2015-02-05 | Sanofi Sa | Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica |
LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
CN115093480A (zh) | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
EP2992017B1 (en) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
JP6453855B2 (ja) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
JP6563906B2 (ja) | 2013-05-31 | 2019-08-21 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Pd−1に結合する抗原結合蛋白質 |
CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物,其制备方法和用途 |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
CN111491362B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
AU2017252640A1 (en) * | 2016-04-19 | 2018-12-06 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
US10533007B2 (en) * | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
-
2019
- 2019-04-24 KR KR1020207033384A patent/KR20210005106A/ko active Search and Examination
- 2019-04-24 BR BR112020021539-2A patent/BR112020021539A2/pt unknown
- 2019-04-24 SG SG11202010463TA patent/SG11202010463TA/en unknown
- 2019-04-24 CA CA3097865A patent/CA3097865A1/en active Pending
- 2019-04-24 CN CN201980027881.7A patent/CN112074516A/zh active Pending
- 2019-04-24 CN CN202011468364.4A patent/CN112521387B/zh active Active
- 2019-04-24 MX MX2020011234A patent/MX2020011234A/es unknown
- 2019-04-24 AU AU2019261582A patent/AU2019261582A1/en not_active Abandoned
- 2019-04-24 EP EP19727780.9A patent/EP3784670B1/en active Active
- 2019-04-24 US US17/049,612 patent/US20210267964A1/en active Pending
- 2019-04-24 EP EP23211253.2A patent/EP4353235A2/en active Pending
- 2019-04-24 JP JP2020559472A patent/JP7351850B2/ja active Active
- 2019-04-24 WO PCT/US2019/028823 patent/WO2019209896A1/en unknown
- 2019-04-24 PE PE2020001652A patent/PE20210160A1/es unknown
- 2019-04-25 TW TW108114491A patent/TW202014420A/zh unknown
-
2020
- 2020-10-20 IL IL278173A patent/IL278173A/en unknown
- 2020-10-21 CO CONC2021/0006672A patent/CO2021006672A2/es unknown
- 2020-10-21 CL CL2020002719A patent/CL2020002719A1/es unknown
- 2020-10-21 CO CONC2020/0013155A patent/CO2020013155A2/es unknown
- 2020-11-24 ZA ZA2020/07307A patent/ZA202007307B/en unknown
-
2023
- 2023-09-14 JP JP2023149057A patent/JP2024001030A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202014420A (zh) | 2020-04-16 |
CN112521387A (zh) | 2021-03-19 |
AU2019261582A1 (en) | 2020-11-12 |
CO2020013155A2 (es) | 2021-06-10 |
PE20210160A1 (es) | 2021-01-26 |
JP2024001030A (ja) | 2024-01-09 |
ZA202007307B (en) | 2023-01-25 |
CN112074516A (zh) | 2020-12-11 |
US20210267964A1 (en) | 2021-09-02 |
SG11202010463TA (en) | 2020-11-27 |
KR20210005106A (ko) | 2021-01-13 |
CN112521387B (zh) | 2023-08-22 |
EP3784670A1 (en) | 2021-03-03 |
JP7351850B2 (ja) | 2023-09-27 |
CO2021006672A2 (es) | 2021-06-10 |
EP4353235A2 (en) | 2024-04-17 |
MX2020011234A (es) | 2020-11-11 |
IL278173A (en) | 2020-11-30 |
EP3784670B1 (en) | 2023-11-29 |
JP2021522249A (ja) | 2021-08-30 |
WO2019209896A1 (en) | 2019-10-31 |
BR112020021539A2 (pt) | 2021-01-19 |
CA3097865A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021006672A2 (es) | Moduladores de nlrp3 | |
CO2020000227A2 (es) | Moduladores de nlrp3 | |
CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2018002759A1 (es) | Compuestos de pirrolotriazina como inhibidores de tam. | |
CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
CO2018005954A2 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
UY36077A (es) | Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen | |
CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
CL2019003515A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina. | |
DOP2021000071A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
DOP2021000021A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
CL2020001093A1 (es) | Proceso para preparar el benzotiofen-2-il boronato. | |
EA202090283A1 (ru) | Модуляторы nlrp3 | |
EA202092539A1 (ru) | Модуляторы nlrp3 | |
MX2020004871A (es) | Derivados de acido cafeico y sus usos. | |
CR20190110A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 |